Gabapentin Update

Key Questions for Practitioners

Overview

Effective May 1, 2024, all Gabapentin products will be Schedule V controlled substances in Utah.

All applicable provisions of recently passed Utah House Bill 260 CONTROLLED SUBSTANCES AMENDMENTS that affected UCA 58-37-4 Schedules of controlled substances and other licensure board regulations will apply to Gabapentin.

Please review all controlled substance security, storage, record keeping, inventory, prescribing, and dispensing requirements.

This document is not intended to be an all-inclusive overview.

Authorized practitioners MUST hold a Utah Controlled Substance License and a DEA registration to prescribe, administer, or dispense a controlled substance in the State of Utah.

Only practitioners with a Utah Controlled Substance license and a DEA registration may issue prescriptions for Gabapentin or order the direct administration or dispensing of Gabapentin to a patient.

After **May 1, 2024**, any new orders for Gabapentin issued by a practitioner WITHOUT a Utah Controlled Substance license and a DEA registration will not be valid and MAY NOT be administered or dispensed.

Prescription orders (including refills) issued for Gabapentin prior to May 1, 2024, will not be affected.

It is not legal to distribute Gabapentin samples in Utah.

Frequently Asked Questions

Effective Date	May 1, 2024
How does moving gabapentin to Schedule V affect prescribing practitioners?	 Practitioners will no longer be able to prescribe Gabapentin unless they have a Utah Controlled Substance License and a DEA registration As of January 1, 2024, all prescriptions for controlled substances must be electronically submitted unless otherwise exempted. Gabapentin dispensed in Utah will continue to appear on Controlled Substance Database (CSD) reports since tracking began as a drug of concern in 2019. Prescribers must comply with the legal standards for prescribing controlled substances promulgated by their licensure board.
How does moving gabapentin to Schedule V affect dispensing practitioners?	Dispensing practitioners may not dispense Gabapentin.
How does moving gabapentin to Schedule V affect pharmacies?	 Pharmacies must perform an initial Gabapentin inventory on or after May 1, but before May 31, 2024. Pharmacies must include Gabapentin in their Annual Controlled Substance inventories. Gabapentin dispensing data will not successfully upload to the Controlled Substance Database if the prescriber does not have a DEA number, so please ensure that your computer system reflects the correct prescriber data. Dispensing data for Gabapentin must be transmitted to the CSD system in accordance with 58-37f. Prescription orders (including refills) issued for Gabapentin prior to May 1, 2024, will not be affected. Schedule V prescriptions are valid for one year from the date of issue.